Head and Neck Cancer Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Head and Neck Cancer Pipeline Insight, 2024," report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Head and Neck cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Head and Neck Cancer Pipeline Report
• DelveInsight's Head and Neck Cancer pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Head and Neck Cancer treatment.
• The leading companies working in the Head and Neck Cancer Market include Innate Pharma, GlaxoSmithKline, Debiopharm, MacroGenics, Takeda Oncology, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., PNP Therapeutics, Inc., IntraGel Therapeutics, Incyte Corporation, Corregene Biotechnology Co., Ltd, TyrNovo Ltd., BioNTech SE, Adlai Nortye Biopharma Co., Ltd., Merck KGaA, Aveta Biomics, Inc., Cellectar Biosciences, Inc., Nanobiotix, ALX Oncology, Nektar Therapeutics, Ikena Oncology, AstraZeneca, Arcus Biosciences Inc., Roche, Vaccinex, Pfizer, Astex Pharmaceuticals, Inc., Eli Lilly and Company, Bayer HealthCare, Kura Oncology, Cue Biopharma, Shanghai Henlius Biotech, Merus N.V., NanoCarrier Co., Ltd., Alkermes, Inc., Rubius Therapeutics, iTeos Belgium SA, Transgene, Boehringer Ingelheim, Immutep S.A.S., Compugen Ltd, Galectin Therapeutics, BioAtla, Inc., Betta Pharmaceuticals Co., Ltd., Jacobio Pharmaceuticals Co., Ltd., CytomX Therapeutics, Advaxis, Inc., Inhibrx, Inc., Celldex Therapeutics, Carisma Therapeutics Inc., Intensity Therapeutics, Inc., I-Mab Biopharma, Quadriga Biosciences Inc., Checkpoint Therapeutics, Inc., Wellmarker Bio, Genentech, Inc., Pionyr Immunotherapeutics Inc., Cyteir Therapeutics, Inc., Klus Pharma Inc., Bicycle Therapeutics, Palleon Pharmaceuticals, Inc., Rapa Therapeutics, SN BioScience, Memgen Inc., and others.
• Promising Head and Neck Cancer Pipeline Therapies in the various stages of development include TAK-981, Cetuximab, Avelumab, Cisplatin, BMX-001, Paclitaxel, 2% Rebamipide liquid, Porfiromycin, and others.
• November 2023: EMD Serono Research & Development Institute Inc. announced a study of Phase 3 clinical trials for Xevinapant (Debio 1143). The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) who are ineligible to receive cisplatin-based chemoradiation concurrently. Study details include: Study duration: Participants will be followed until the last on-study participant reaches his/her 60-month post-randomization visit, a decision to end the study has been triggered, or until premature discontinuation from study, whichever occurs first. Treatment duration: 18 weeks, consisting of six 3-week cycles. Health measurement/observation: Improved Disease-Free Survival. Visit frequency: Weekly visit during combination therapy period, once every 3 weeks during monotherapy period, and every 3, 4, or 6 months during the Disease-Free Survival Follow-up period in Year 1, 2 and 3, or 4 and 5 (with telephone contact in between), respectively, and every 3 months (telephone visits allowed) during the Overall Survival Follow-up period.
• November 2023: Providence Health & Services announced a study of Phase 1 clinical trials for Anti-OX40 antibody administration. The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma. This phase Ib clinical trial uses MEDI6469 at various dose intervals prior to definitive surgical resection of patients with stage III and IV Oral Head and Neck Squamous Cell Carcinoma (OHNSCC) with the primary objective of determining the safety and feasibility of preoperative MEDI6469 administration. In addition, tumor tissue and peripheral blood will be obtained for exploratory immunologic end points including measurements of tumor infiltrating immune cell populations based on flow cytometry and immunohistochemistry as well as circulating immunological parameters that may correlate with changes induced by MEDI6469 administration.
• November 2023: BioNTech SE announced a study of Phase 2 clinical trials for BNT113 and Pembrolizumab. An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT).
• November 2023: Adlai Nortye Biopharma Co. Ltd announced a study of Phase 3 clinical trials for Buparlisib & Paclitaxel. This study is to assess the impact on overall survival of the combination of Buparlisib and paclitaxel compared to paclitaxel alone in patients with prior anti PD 1/anti PD L1 monotherapy; prior anti PD 1/anti PD L1 therapy in combination with platinum-based therapy; or after sequential treatment of anti PD 1/anti PD L1 therapy, either prior to or post, platinum-based therapy.
• November 2023: Incyte Biosciences International Sàrl announced a study of Phase 2 clinical trials for Retifanlimab and INCAGN02385. The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
• November 2023: TyrNovo Ltd. announced a study of Phase 1 & 2 clinical trials for NT219. This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX® (cetuximab) in adults with recurrent and/or metastatic solid tumors.

Request a sample and discover the recent advances in Head and Neck Cancer Treatment Drugs @ Head and Neck Cancer Pipeline Report- https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

n the Head and Neck Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Head and Neck cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Head and Neck Cancer Overview
Head and neck cancer is a collective term that includes several different types of cancers. Cancers of the head and neck are categorized by the area in which they begin. This includes the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. The most common type of head and neck cancer is squamous cell carcinoma of the head and neck (HNSCCA).

Find out more about Head and Neck Cancer Therapeutics Assessment @ Head and Neck Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Head and Neck Cancer Emerging Drugs Profile
• Monalizumab: Innate Pharma
• Niraparib: GlaxoSmithKline
• Xevinapant: Debiopharm
• Enoblituzumab: MacroGenics

Head and Neck Cancer Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Head and Neck cancer. The Head and Neck Cancer companies which have their Head and Neck cancer drug candidates in the most advanced stage, i.e. phase III include, Innate Pharma.

DelveInsight's Head and Neck Cancer pipeline report covers around 150+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Head and Neck Cancer Pipeline Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Learn more about the emerging Head and Neck Cancer Pipeline Therapies @ Head and Neck Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Head and Neck Cancer Pipeline Report
• Coverage- Global
• Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Head and Neck Cancer Companies- Innate Pharma, GlaxoSmithKline, Debiopharm, MacroGenics, Takeda Oncology, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., PNP Therapeutics, Inc., IntraGel Therapeutics, Incyte Corporation, Corregene Biotechnology Co., Ltd, TyrNovo Ltd., BioNTech SE, Adlai Nortye Biopharma Co., Ltd., Merck KGaA, Aveta Biomics, Inc., Cellectar Biosciences, Inc., Nanobiotix, ALX Oncology, Nektar Therapeutics, Ikena Oncology, AstraZeneca, Arcus Biosciences Inc., Roche, Vaccinex, Pfizer, Astex Pharmaceuticals, Inc., Eli Lilly and Company, Bayer HealthCare, Kura Oncology, Cue Biopharma, Shanghai Henlius Biotech, Merus N.V., NanoCarrier Co., Ltd., Alkermes, Inc., Rubius Therapeutics, iTeos Belgium SA, Transgene, Boehringer Ingelheim, Immutep S.A.S., Compugen Ltd, Galectin Therapeutics, BioAtla, Inc., Betta Pharmaceuticals Co., Ltd., Jacobio Pharmaceuticals Co., Ltd., CytomX Therapeutics, Advaxis, Inc., Inhibrx, Inc., Celldex Therapeutics, Carisma Therapeutics Inc., Intensity Therapeutics, Inc., I-Mab Biopharma, Quadriga Biosciences Inc., Checkpoint Therapeutics, Inc., Wellmarker Bio, Genentech, Inc., Pionyr Immunotherapeutics Inc., Cyteir Therapeutics, Inc., Klus Pharma Inc., Bicycle Therapeutics, Palleon Pharmaceuticals, Inc., Rapa Therapeutics, SN BioScience, Memgen Inc., and others.
• Head and Neck Cancer Pipeline Therapies- TAK-981, Cetuximab, Avelumab, Cisplatin, BMX-001, Paclitaxel, 2% Rebamipide liquid, Porfiromycin, and others.

Dive deep into rich insights for new drugs for Head and Neck Cancer Treatment, Visit @ Head and Neck Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Head and Neck cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Head and Neck cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Monalizumab: Innate Pharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Enoblituzumab: MacroGenics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IK-175: Ikena Oncology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Research programme: cancer vaccines - Voltron Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Head and Neck cancer Key Companies
21. Head and Neck cancer Key Products
22. Head and Neck cancer- Unmet Needs
23. Head and Neck cancer- Market Drivers and Barriers
24. Head and Neck cancer- Future Perspectives and Conclusion
25. Head and Neck cancer Analyst Views
26. Head and Neck cancer Key Companies
27. Appendix

For further information on the Head and Neck Cancer Pipeline therapeutics, reach out to Head and Neck Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
https://theventurecation.com/author/germanydennydones/
https://blogstudiio.com/fabry-disease-market-size/
https://meccapost.com/author/germanydennydones/
https://kitmaker.net/profile/yashveer-bhardwaj
http://www.costaricajobsearch.com/author/germanydennydones/
https://keralaclick.com/classified-advertising/user/profile/182882
https://aviator.forex.pm/?qa=user/germanydennydones
https://careers.coloradopublichealth.org/employers/2926283-delveinsight
https://www.heavyironjobs.com/profiles/4448319-denny-dones
https://jobs.blooloop.com/employers/2614577-delveinsight
https://www.animaljobsdirect.com/employers/2926436-delveinsight
https://jobs.windomnews.com/employers/2926467-delveinsight
https://jobs.fsoma.org/employers/2926471-delveinsight
https://jobs.thetab.com/employers/1458246-delveinsight
https://forum.squarespace.com/profile/421527-dennydonesgermany/?tab=field_core_pfield_1

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

This release was published on openPR.